Review - Strategi dan Tantangan Pengembangan Vaksin Demam Berdarah
Abstract
Keywords
Full Text:
PDFReferences
Adnan, Muhammad, Nuhamunada, Matin, Hidayati, Lisna, and Wijayanti, Nastiti. 2020. In silico vaccine design against dengue virus type 2 envelope glycoprotein. Hayati Journal of Biosciences, 27(3): 228–240.
Amin, H.Z., dan Saleha, S. 2013. Perkembangan Mutakhir Vaksin Demam Berdarah. eJKI, 1(3).
Bhamarapravati, N., dan Sutee Y.2000. Live attenuated tetravalent dengue vaccine.Vaccine, 26(18): 44-7.
Bhatt, S., Peter, W.G., Oliver, J. B., Jane, P. M., Andrew, W.F., Cathrine, L.M. 2013. The global distribution and burden of dengue. Nature, 496(7446): 504–5077
Capeding, M.R., Tran, N.H., Hadinegoro, S.R.S., Ismail, Chotpitayasunondh, T., Chua, M.N. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebocontrolled trial. The Lancet, 384 (9951):1358–65.
Guy, B., Mellanie, S., dan Jean, L. 2010. Development of sanofi pasteur tetravalent dengue vaccine. Human Vaccines, 6(9): 696-705.
Kementrian Kesehatan RI. 2010. Data kasus DBD per bulan di Indonesia tahun 2010, 2009, dan 2008. Jakarta : Departemen Kesehatan RI.
Konishi, E. 2011. Issues related to recent dengue vaccine development. Tropi Medi and Health, 39(4):63-71.
Marbawati, Dewi dan Tri Wijayanti. 2014. Vaksin dengue, tantangan, perkembangan dan strategi. BALABA, 10(01): 39-46.
Guirakhoo, F., Weltzin, R., Chambers, T.J., Zhang, Z.-X., Soike, K., Ratterree, M. 2000. Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates. Journal of Virology, 74(12):5477– 85.
Khetarpal, Niyati dan Ira Khanna. 2016. Review article dengue fever: causes, complication and vaccine strategies. Journal Of Immunology Research.
Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, Saluzzo JF. 2006. Immunogenicity and safety of two liveattenuated tetravalent dengue vaccine formulations in healthy Australian adults.Vaccine, 24(9):1238-41.
Modis, Y., Steven, O., David, C., and Stephen C. H. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. Journal of Virology, 79(2):1223–1231
Meiranty, C. Pangerapan dan Beivy J. Kolondam. 2015. Peran gen struktural, gen non structural dan untranslated region dalam virus dengue. Jurnal Biomedik, 7(2).
Paisal dan Subangkit. 2013. Strategi pengembangan vaksin dengue. Kajian.
Rajapakse, S., Rodrigo, C., dan Rajapakse, A. 2012. Treatment of dengue fever. Infection and Drug Resistance, 103:103–12.
Russell PK, Nisalak A.1967. Dengue virus identification by the plaque reduction neutralization test. J Immunol, 99(2):91-6.
Stephenson, JR. 2005. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ, 83:308-14.
Simmons, P., Farrar, J., Nguyen, V., and Wills, B. 2012. Dengue. New Eng J Med, 366(15):1423-32.
Tang, K.F. and Ooi, E.E. 2012. Diagnosis of dengue: an update. Expert Review of Anti-infective Therapy, 10(8):895–907
Villar, L., Dayan, G.H., Arredondo-García, J.L., Rivera, D.M., Cunha, R., Deseda, C. 2015. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. New England Journal of Medicine, 372(2):113–123.
Wilder, S.A., Hombach, J., Ferguson, N., Selgelid, M., O’Brien, K., Vannice, K. 2018. Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis, 3099(18):3049
DOI: https://doi.org/10.35799/pha.11.2022.40486
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 PHARMACON
![Creative Commons License](http://licensebuttons.net/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
![]() | Publisher : | ![]() | Cooperation With : |
![Creative Commons License](https://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.